

YOU ARE CORDIALLY INVITED TO

Celltrion Product Theater

at the 2024 Digestive Disease Week®

Understanding ZYMFENTRA™:

The first and only subcutaneous infliximab offering
a different therapeutic option in UC and CD maintenance^{1,2}



Speaker:

Stephen B. Hanauer, MD

Professor of Medicine
Medical Director, Digestive Health Center
Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine

Location:

DDW Theater 2

Time:

12:50 P.M. - 1:35 P.M.

Date:

May 21, 2024

Indications and Usage

ZYMFENTRA is indicated in adults for the maintenance treatment of moderate-to-severe UC or moderate-to-severe CD following an IV infliximab product.

Important Safety Information

WARNING: SERIOUS INFECTIONS and MALIGNANCY

- Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
- Discontinue ZYMFENTRA if a patient develops a serious infection or sepsis.
- Perform test for latent TB; if positive, start treatment for TB prior to starting ZYMFENTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab.
- Post-marketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males.

Contraindications

ZYMFENTRA is contraindicated in patients with a history of a severe hypersensitivity reaction to other infliximab products, any of its ingredients, or any murine proteins. Reactions have included anaphylaxis.

Please see additional important safety information and full Prescribing Information including **BOXED WARNING** available in the exhibit

The Product Theater content and views expressed therein are those of the sponsor and not of the Digestive Disease Week®.

CD, Crohn's Disease; **HSTCL**, hepatosplenic T-cell lymphoma; **IV**, intravenous;
TB, tuberculosis; **TNF**, tumor necrosis factor; **UC**, Ulcerative Colitis.

References: 1. ZYMFENTRA™ Prescribing Information, Celltrion, Inc., 2023. 2. Data on file. Celltrion, Inc.



ZYMFENTRA™ is a trademark of Celltrion, Inc., used under license.
© Celltrion Co., Ltd. 2024 US-ZYM-24-00248